Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Abstract The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour...

Full description

Bibliographic Details
Main Authors: Guntram Schernthaner, Naim Shehadeh, Alexander S. Ametov, Anna V. Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Janež, Péter Kempler, Ilze Konrāde, Nebojša M. Lalić, Boris Mankovsky, Emil Martinka, Dario Rahelić, Cristian Serafinceanu, Jan Škrha, Tsvetalina Tankova, Žydrūnė Visockienė
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Cardiorenal protection
Glucose lowering drugs
Clinical inertia
Online Access:http://link.springer.com/article/10.1186/s12933-020-01154-w

Internet

http://link.springer.com/article/10.1186/s12933-020-01154-w

Similar Items